52 results
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
8 Aug 24
Results of Operations and Financial Condition
8:27am
engagement Value and HEOR evidence generation US Center onboarding US supply chain, logistics and systems testing Obe-cel MHRA authorization … Obe-cel is similar to Erlangen CD19 CART Differentiated CD19 engagement (fast off-rate) Off Rate: Kd [S-1] ]1 - S 1 - [M a K : e Ra t - On Other CD19
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
5 Jun 24
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc
4:35pm
or hospitals. With our experience in gene therapy, transplantation and oncology, we aim to provide high levels of service and scientific engagement … engagement culture and values”. These core principles—Focus, Respect, Integrity and Breakthrough—inform and support our directors as they provide
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
5 Jun 24
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc
4:35pm
structure, resourcing and terms of engagement for the external auditor annually. Notes to resolutions 4, 5, 6 and 7 Re-election of Directors
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
engagement Value and HEOR evidence generation US Center onboarding US supply chain, logistics and systems testing Obe-cel MHRA authorization application … space for CAR T Obe-cel is similar to Erlangen CD19 CART Differentiated CD19 engagement (fast off-rate) Off Rate: Kd [S-1] ]1 - S 1 - [M a K : e Ra t
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
limitations of current treatments and provide innovative options for patients.
Obe-cel has an optimized engagement of the CD19 target designed … , transplantation and oncology, we aim to provide high levels of service and scientific engagement at these treatment centers, and to pilot and establish
8-K
EX-99.2
1su7jvmg4qqk
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-1.1
wlnmk62x mgqg3f
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-10.1
sxiik5qje qf
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
6-K/A
EX-99.2
xtlv0
6 Jul 23
Current report (foreign) (amended)
5:38pm
6-K
EX-99.2
y8p6umukhvc5domr
6 Jun 23
Current report (foreign)
8:18am
6-K
EX-1.1
zq1ot7pxes19lrtams
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
424B5
llutodmxgbx hd
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
6ibh poefhg4xs
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-1
hzrsdrpcb
1 Jul 22
Current report (foreign)
5:15pm
6-K
EX-99.1
nyphpxer4e86s0y bt
1 Jun 22
Current report (foreign)
5:19pm
6-K
EX-99.1
zegc0eju6q2a6i0
8 Nov 21
Securities Purchase Agreement
5:28pm
424B5
49d fjr4rb3
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
b60 mc02ir4pke
6 Aug 21
Shelf registration (foreign)
2:30pm